Milner joins Cambridge-ARIA collaboration to create new technologies for transforming brain health
We are delighted that the Milner Therapeutics Institute (MTI) has joined a three-year collaboration with the science funding agency ARIA and multiple Cambridge partners, to engineer a new generation of neuro-technologies designed to treat depression, dementia, chronic...
Milner Institute awarded £7m to enable Functional Genomics Screening Laboratory as part of UK wide initiative
We’re delighted to announce that the Medical Research Council (MRC), in collaboration with the Biotechnology and Biological Sciences Research Council (BBSRC), awarded £7m to help establish the MRC-AstraZeneca-University of Cambridge joint Functional Genomics...
Drug Discovery World interviews Milner Institute Head of Research
Earlier this year, our Head of Research Dr Nicola McCarthy sat down with Megan Thomas, Multimedia Editor at Drug Discovery World, to explore Nicola’s role at the MTI, her career journey, and her views on the current opportunities and challenges in the field of drug...
Cambridge Biomedical Campus welcomes Milner Affiliate Cytiva
Global life sciences leader and Milner affiliate Cytiva recently established a footprint in the Jeffrey Cheah Biomedical Centre on the Cambridge Biomedical Campus (CBC), further developing relationships with the Milner Institute and the Cambridge Stem Cell Institute...